Thursday, October 5, 2017: 12:30 PM Background. Candida auris is an emerging nosocomial pathogen that is resistant to Fluconazole and variably susceptible to other systemic drug classes. Treatment with echinocandins has been recommended based on MICs in the susceptible range, but supporting in vivo data is lacking.
Pharmacodynamic Optimization for the Treatment of Invasive Candida auris
Background. Candida auris is an emerging, nosocomial multidrug-resistant threat with high treatment failure rate and mortality. The optimal antifungal agent to use and susceptibility breakpoints are based on limited clinical data.
Methods. Nine clinical C. auris strains were used. MICs were determined by CLSI standards. Drug treatment studies consisted of: fluconazole (FLC) dose range 0.78-200 mg/kg/12 h, micafungin (MFG) dose range 0.3125-80 mg/kg/24 h, or amphotericin B deoxycholate (AMB) dose range 0.0.78-20 mg/kg/24 hours. Plasma PK was previously determined in the murine model for all three drugs. A 96 h neutropenic murine model of invasive candidiasis (IC) was used for all studies. The Emax Hill equation was used to model the dose-response data to PK/PD index AUC/MIC (FLC and MFG) and Cmax/MIC (AMB). The static and 1 log kill doses (when achieved) and the associated PK/PD targets (AUC/MIC or Cmax/MIC) were determined and compared with previous murine IC studies with C. albicans, C. glabrata, and C. parapsilosis. Results. MIC range: FLC 2-256 mg/l, MFG 0.125-4 mg/l, and AMB 0.38-6 mg/l. Dose-dependent activity was observed with all three drugs. Net stasis was achieved against seven strains for FLC, eight strains for MFG, and eight strains for AMB. However, MFG performed significantly better than comparators for cidal endpoints. A 1 log kill endpoint was achieved in eight strains for MFG, whereas this endpoint was only achieved in one strain for FLC and three strains for AMB Conclusion. MFG was the most potent drug over the dose range achieving up to 2 log kill against eight of nine strains. PK/PD targets for C. auris against FLC and AMB were similar to other Candida species; however, MFG targets were ≥20-fold lower than C. albicans, C. glabrata, and C. parapsilosis. Using the median stasis targets and human PK for each drug, resistance thresholds could be 16 mg/l for FLC, 2-4 mg/l for MFG, and 1-2 mg/l for AMB.
Disclosures. All authors: No reported disclosures. Methods. All patients age 18 or greater with a first episode of CBSI by blood culture from 1/2002 to 1/2015, admitted to Barnes-Jewish Hospital, a tertiary referral hospital in St. Louis, MO, were included. We collected data on demographics, comorbidities, laboratory values, vital signs, indwelling devices, and medical treatments of interest from the electronic medical record. We analyzed the potential predictor variables using univariate logistic regression. Variables associated with mortality were considered for model inclusion. The final model was built using multivariable binary logistic regression. A predictive equation was created, and a receiver-operator curve (ROC) was calculated to determine the appropriate cut-off points and c-statistic.
Risk Predictive Model for 90-Day Mortality in
Results. Of the 1873 episodes of CBSI identified, 789 (42%) resulted in death in 90 days. The variables included in this model were age (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) ≥70: 0.560, ; history of CAD (1.616, 1.171-2.230), chronic liver disease (2.247, 1.327-3.806); maximum heart rate (1.496, 1.126-1.989) and temperature (0.537, 0.408-0.708 
